Vanda Pharmaceuticals Inc. $VNDA Stake Increased by AIGH Capital Management LLC

AIGH Capital Management LLC boosted its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 37.6% in the 1st quarter, Holdings Channel reports. The firm owned 2,750,000 shares of the biopharmaceutical company’s stock after buying an additional 751,569 shares during the quarter. Vanda Pharmaceuticals accounts for approximately 2.6% of AIGH Capital Management LLC’s portfolio, making the stock its 7th biggest position. AIGH Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $19,002,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Vanda Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock worth $17,900,000 after buying an additional 14,336 shares during the period. Millennium Management LLC boosted its holdings in Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after acquiring an additional 1,470,898 shares during the period. Krensavage Asset Management LLC boosted its holdings in Vanda Pharmaceuticals by 15.2% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock valued at $5,890,000 after acquiring an additional 155,505 shares during the period. Empire Financial Management Company LLC boosted its holdings in Vanda Pharmaceuticals by 46.2% during the 4th quarter. Empire Financial Management Company LLC now owns 1,108,245 shares of the biopharmaceutical company’s stock valued at $9,775,000 after acquiring an additional 350,154 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in Vanda Pharmaceuticals by 552.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 708,428 shares of the biopharmaceutical company’s stock valued at $6,248,000 after acquiring an additional 599,818 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock opened at $6.58 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.15 and a current ratio of 2.16. The company has a market capitalization of $395.66 million, a PE ratio of -1.62 and a beta of 0.60. The company has a 50 day moving average price of $6.25 and a 200-day moving average price of $7.07. Vanda Pharmaceuticals Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.The firm had revenue of $51.72 million during the quarter, compared to the consensus estimate of $54.98 million. As a group, equities analysts forecast that Vanda Pharmaceuticals Inc. will post -2.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on VNDA. Wall Street Zen lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Monday, April 20th. Finally, HC Wainwright restated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.30.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.